

Product Description

Pioneering GTPase and Oncogene Product Development since 2010

TAF12 RABBIT PAB

货号: S217878

产品全名: TAF12 兔多抗 基因符号 TAF2J; TAFII20

UNIPROT ID: Q16514 (Gene Accession - BC011986)

背景: Control of transcription by RNA polymerase II involves the basal transcription machinery which is a collection of proteins. These proteins with RNA polymerase II, assemble into complexes which are modulated by transactivator proteins that bind to cis-regulatory elements located adjacent to the transcription start site. Some modulators interact directly with the basal comple,x whereas others may act as bridging proteins linking transactivators to the basal transcription factors. Some of these associated factors are weakly attached while others are tightly associated with TBP in the TFIID complex. Among the latter are the TAF proteins.

抗原: Fusion protein of human TAF12

经过测试的应用: ELISA, IHC

推荐稀释比: IHC: 25-100; ELISA: 2000-5000


种属反应性: Rabbit 克隆性: Rabbit Polyclonal

亚型: Immunogen-specific rabbit IgG 纯化: Antigen affinity purification 种属反应性: Human, Mouse


成分: PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

研究领域: Epigenetics and Nuclear Signaling


储存和运输: Store at -20°C. Avoid repeated freezing and thawing




Immunohistochemistry analysis of paraffin embedded Human liver cancer tissue using 217878(TAF12 Antibody) at a dilution of 1/35(Cytoplasm and Nucleus).



In comparision with the IHC on the left, the same paraffin-embedded Human liver cancer tissue is first treated with the fusion protein and then with 217878(Anti-TAF12 Antibody) at dilution 1/35.



The image on the left is immunohistochemistry of paraffinembedded Human esophagus cancer tissue using 217878(Anti-TAF12 Antibody) at a dilution of 1/35.



In comparision with the IHC on the left, the same paraffin-embedded Human esophagus cancer tissue is first treated with fusion protein and then with D223279(Anti-TAF12 Antibody) at dilution 1/35.



Product Description

Pioneering GTPase and Oncogene Product Development since 2010